{
    "nctId": "NCT05559164",
    "briefTitle": "Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted",
    "officialTitle": "STACIE: Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy",
    "overallStatus": "RECRUITING",
    "conditions": "Cardiac Toxicity, Early-stage Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Number of Participants With at Least One Adverse Event will be measured using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 for five years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically and/or cytologically confirmed diagnosis of Stage I-III female breast cancer (including inflammatory breast cancer)\n* Scheduled to receive neoadjuvant/adjuvant HER2 targeted therapy\n* Between \u226518 years of age\n* Female patients of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment. Female patients must agree to use effective barrier contraception during the period of therapy\n* Baseline LVEF \u2265 50%\n* Prior cancers allowed if no evidence of disease in last 5 years\n* ECOG 0-2\n* No prior history of treatment with HER2 targeted therapy or anthracyclines based chemotherapy\n* Adequate bone marrow function:\n\nI. ANC \u2265 1000/uL II. platelet count \u2265 100,000/uL III. hemoglobin \u2265 9.0 g/dL\n\n\u2022 Adequate hepatic function: I. Total bilirubin \u2264 1.5 X ULN II. AST (SGOT) \u2264 5 X ULN III. ALT (SGPT) \u2264 5 X ULN\n\n* Adequate renal function, Creatinine \\< 1.5x institutional ULN or calculated creatinine clearance \u2265 50 mL/min as estimated using the Cockcroft-Gault formula\n* Ability to understand the nature of this study protocol and give written informed consent\n* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures\n\nExclusion Criteria:\n\n* Participants with stage IV breast cancer\n* Participants currently taking statins\n* Uncontrolled hypertension (systolic blood pressure \\>190 mm Hg or diastolic blood pressure \\>100 mm Hg)\n* No active liver disease\n* Current use of CYP 3A4 inhibitors\n* Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study\n* Life expectancy \\< 12 weeks\n* Pregnancy (positive pregnancy test) or lactation\n* Pre-existing sensory neuropathy \\> grade one\n* Has significant cardiovascular disease, such as:\n\nLVEF \\< 50% at baseline as assessed by ECHO (preferred) i) Class III or Class IV myocardial disease as described by the New York Heart Association ii) Recent history (within 6 months prior to enrollment) of myocardial infarction; or iii) Symptomatic arrhythmia at the time of randomization\n\n* Major surgery without complete recovery in the past four weeks prior to screening\n* Concurrent active infection\n* Participant with uncontrolled and/ or active infection with HIV, Hepatitis B or Hepatitis C\n* Participant who has a history of allergy or hypersensitivity to any of the study drugs\n* Participant with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis\n* Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}